+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Collagenase 3 - Pipeline Review, H2 2020

  • ID: 5189158
  • Drug Pipelines
  • October 2020
  • Region: Global
  • 62 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Pfizer Inc
  • Pharmahungary Group
  • MORE
Summary

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Collagenase 3 - Pipeline Review, H2 2020, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Knee Osteoarthritis, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.

Furthermore, this report also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Pfizer Inc
  • Pharmahungary Group
  • MORE
Introduction
  • Report Coverage
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
  • Aquilus Pharmaceuticals Inc
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Pharmahungary Group
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles

pentosan polysulfate sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PF-152 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 01, 2020: Zilosul reduces pain in patients with knee osteoarthritis
  • Sep 28, 2020: Paradigm’s clear path towards Zilosul’s OA phase 3 clinical trial and product registration in Europe
  • Aug 11, 2020: Paradigm receives critical approvals and feedback from agencies to progress MPS clinical and commercial development
  • Jul 30, 2020: Paradigm reports: 65% Pain reduction in OA patients treated under the US FDA Expanded Access Program
  • Apr 30, 2020: Paradigm reports: Under the US FDA Expanded Access Program treatment is completed for all of the ten planned patients. Paradigm granted Orphan Status by US FDA for MPS-I
  • Apr 06, 2020: Paradigm reports very encouraging realworld data ahead of its phase 3 OA Clinical Trial
  • Feb 21, 2020: Paradigm reports positive pre-IND meeting with US FDA
  • Feb 18, 2020: Paradigm reports: first patient dosed in USA under FDA approved expanded access program
  • Feb 13, 2020: Paradigm presents MPS VI poster at the World MPS Symposium in Orlando, Florida
  • Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS
  • Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period
  • Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis
  • Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial
  • May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic
  • Apr 16, 2019: Paradigm’s knee osteoarthritis study meets secondary endpoints
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2020
  • Pipeline by Pfizer Inc, H2 2020
  • Pipeline by Pharmahungary Group, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Aquilus Pharmaceuticals Inc
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Pharmahungary Group
Note: Product cover images may vary from those shown
Adroll
adroll